Leica BOND RX – A New IHC & ISH Research Platform
The Freedom to Discover
Chicago, USA. Leica Microsystems announce the release of Leica BOND RX; the world’s first truly open, fully automated IHC and ISH platform for biotechnology and pharmaceutical research. This new system delivers researchers the freedom they need to make breakthrough discoveries for new cancer treatments.
For the first time, the efficiency of full automation is matched to unlimited reagent selection and freely customizable protocols. Where previous research platforms were restrictive, the new Leica BOND RX offers unprecedented choice with researchers able to select the ideal reagents, dispense sequences and incubation conditions for any study.
Drug discovery trials and cancer research are further enhanced by exceptional staining quality and total tissue care. With precise automation, Leica BOND RX delivers the consistency needed for detailed analysis while the unique Covertile™ system provides maximum protection for every sample so vital information is not lost.
Early and late stage researchers will also appreciate the speed and efficiency of Leica BOND RX. With fast turnaround and virtually no daily maintenance, Leica BOND RX will deliver more valuable research within existing timelines and budgets to effectively bring forward critical insights and new discoveries.
Arnd Kaldowski, President of Leica Biosystems, explains the importance of Leica BOND RX and cancer research: “Over 12 million* people are diagnosed with cancer every year, so research into new treatments is vital. Scientists researching cancer and developing new treatments should be free to choose the reagents and staining protocols they need. By making Leica BOND RX truly open, researchers now have a system to help them bring life-changing breakthroughs closer than ever before.”
Leica BOND RX is available immediately in North America through authorized Leica Microsystems representatives.
For research use only. Leica BOND RX must not be used in diagnostic procedures.
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _
Leica Microsystems is a world leader in microscopes and scientific instruments. Founded as a family business in the nineteenth century, the company’s history was marked by unparalleled innovation on its way to becoming a global enterprise.
Its historically close cooperation with the scientific community is the key to Leica Microsystems’ tradition of innovation, which draws on users’ ideas and creates solutions tailored to their requirements. At the global level, Leica Microsystems is organized in four divisions, all of which are among the leaders in their respective fields: the Life Science Division, Industry Division, Biosystems Division and Medical Division.
Leica Microsystems’ Biosystems Division, also known as Leica Biosystems, offers histopathology laboratories the most extensive product range with appropriate products for each work step in histology and for a high level of productivity in the working processes of the entire laboratory.
The company is represented in over 100 countries with 12 manufacturing facilities in 7 countries, sales and service organizations in 19 countries and an international network of dealers. The company is headquartered in Wetzlar, Germany.
* GLOBOCAN 2008
Cancer Incidence and Mortality Worldwide in 2008